Domov › Akutna mieločna levkemija › Minnesota › Minneapolis
Klinične študije za Akutna mieločna levkemija v Minneapolis, MN
20 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Minneapolis in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Vključevanje udeležencevFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Vključevanje udeležencevFaza 1
- University of Minnesota/Masonic Cancer Center, Minneapolis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi stran
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Vključevanje udeležencevFaza 3
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Vključevanje udeležencevFaza 1/2
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 3
- Masonic Cancer Center, Minneapolis
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Vključevanje udeležencevFaza 3
- University of Minnesota, Minneapolis
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 1/2
- Masonic Cancer Center, Minneapolis
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
Vključevanje udeležencevFaza 1
- Masonic Cancer Center, Minneapolis
Allo HSCT Using RIC and PTCy for Hematological Diseases
Vključevanje udeležencevFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Vključevanje udeležencevFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Vključevanje udeležencevFaza 1/2
- Mark Juckett, MD, Minneapolis
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Vključevanje udeležencevFaza 2
- Masonic Cancer Center at University of Minnesota, Minneapolis
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
Vključevanje udeležencevOpazovalna študija
- University of Minnesota/Masonic Cancer Center, Minneapolis
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Vključevanje udeležencevFaza 2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Vključevanje udeležencevFaza 1
- University of Minnesota, Minneapolis
Študije za Akutna mieločna levkemija v drugih mestih
- Houston, TX85 študij
- New York City, NY51 študij
- Boston, MA44 študij
- Seattle, WA41 študij
- Baldwin Park, CA40 študij
- Columbus, OH35 študij
- Philadelphia, PA34 študij
- Durham, NC33 študij
- Atlanta, GA31 študij
- Tampa, FL29 študij
- Chicago, IL26 študij
- Portland, OR25 študij
Druge študije v Minneapolis
- Nemalicelični pljučni rak27 študij
- Rak dojke27 študij
- Rak jajčnikov24 študij
- Rak prostate23 študij
- Rak (vse vrste)22 študij
- Srčno popuščanje21 študij
- Rak pljuč20 študij
- Kolorektalni rak19 študij
- Rak endometrija18 študij
- Parkinsonova bolezen17 študij
- Srčno-žilne bolezni15 študij
- Bolezen venčnih arterij13 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.